Search

Your search keyword '"Larrat, Sylvie"' showing total 192 results
Start Over Author "Larrat, Sylvie"
192 results on '"Larrat, Sylvie"'

1. SAT-389 HBV and HBsAg strongly reshape the phenotype, function and metabolism of DCs according to patients’ clinical stage

Author

Dumolard, Lucile, primary, Théophile, Gerster, additional, Chuffart, Florent, additional, Decaens, Thomas, additional, Hilleret, Marie-Noëlle, additional, Larrat, Sylvie, additional, Saas, Philippe, additional, Jouvin-Marche, Evelyne, additional, Durantel, David, additional, Marche, Patrice N, additional, Jilkova, Zuzana Macek, additional, and Aspord, Caroline, additional

Published
2024
Full Text
View/download PDF

4. SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy

Author

Truffot, Aurelie, Andreani, Julien, Marechal, Marion Le, Caporossi, Alban, Epaulard, Olivier, Germi, Raphaele, Poignard, Pascal, and Larrat, Sylvie

Subjects
Immunocompromised host -- Care and treatment -- Physiological aspects, Viral antibodies -- Usage -- Health aspects, Antibodies -- Usage -- Health aspects, Health
Abstract

A 72-year-old immunocompromised man in France who had chronic lymphocytic leukemia associated with hypogammaglobinemia for 4 years experienced diarrhea, asthenia, fever, and cough associated with coronavirus disease (COVID-19). Although he [...]

Published
2021
Full Text
View/download PDF

9. The onset of late severe lung impairment in COVID-19 is associated with high inflammation markers at admission and metabolic syndrome markers

Author

Epaulard, Olivier, primary, Le Gouellec, Audrey, additional, Le Marechal, Marion, additional, Nemoz, Benjamin, additional, Borel, Anne-Laure, additional, Dartevel, Anaïs, additional, Gheerbrant, Hubert, additional, Herault, Marie-Christine, additional, Bosseray, Annick, additional, Clavarino, Giovanna, additional, Lupo, Julien, additional, Viglino, Damien, additional, Quenard, Fanny, additional, Candille, Clara, additional, Camara, Boubou, additional, Durand, Michel, additional, Faure, Patrice, additional, Guergour, Dorra, additional, Chidlovski, Elena, additional, Jacob, Marie-Christine, additional, Larrat, Sylvie, additional, Froidure, Marie, additional, Terzi, Nicolas, additional, Quetant, Sébastien, additional, Payen, Jean-François, additional, Colombe, Barbara, additional, Raskovalova, Tatiana, additional, Morand, Patrice, additional, Pierre, Isabelle, additional, Schwebel, Carole, additional, Hamidfar, Rebecca, additional, Bouillet, Laurence, additional, Brion, Jean-Paul, additional, Trocme, Candice, additional, Berthier, Sylvie, additional, Chirica, Carole, additional, Mounayar, Anne-Laure, additional, Blanc, Myriam, additional, Pavese, Patricia, additional, and Toussaint, Bertrand, additional

Published
2022
Full Text
View/download PDF

10. Added value of next-generation sequencing for multilocus sequence typing analysis of a Pneumocystis jirovecii Pneumonia outbreak

Author

Charpentier, Elena, Garnaud, Cecile, Wintenberger, Claire, Bailly, Sebastien, Murat, Jean-Benjamin, Rendu, John, Pavese, Patricia, Drouet, Thibault, Augier, Caroline, Malvezzi, Paolo, Thiebaut-Bertrand, Anne, Mallaret, Marie-Reine, Epaulard, Olivier, Cornet, Muriel, Larrat, Sylvie, and Maubon, Daniele

Subjects
DNA sequencing -- Analysis, Pneumonia -- Genetic aspects -- Risk factors, Organ transplantation -- Health aspects, Health
Abstract

Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic disease that poses a particular threat in healthcare units that manage patients with oncohematologic conditions, patients having received solid organ transplants (SOTs), [...]

Published
2017
Full Text
View/download PDF

14. Persistence at one year of neutralizing antibodies after SARS-CoV-2 infection: Influence of initial severity and steroid use

Author

Epaulard, Olivier, primary, Buisson, Marlyse, additional, Nemoz, Benjamin, additional, Maréchal, Marion Le, additional, Terzi, Nicolas, additional, Payen, Jean-François, additional, Froidure, Marie, additional, Blanc, Myriam, additional, Mounayar, Anne-Laure, additional, Quénard, Fanny, additional, Pierre, Isabelle, additional, Pavese, Patricia, additional, Germi, Raphaele, additional, Grossi, Laurence, additional, Larrat, Sylvie, additional, Poignard, Pascal, additional, and Lupo, Julien, additional

Published
2022
Full Text
View/download PDF

15. Is it possible to hospitalize patients in multiple-bed room without increasing the risk of hospital-acquired influenza? Description of a pragmatic preventive strategy in a French university hospital

Author

Cazzorla, Fabiana, primary, Azzam, Othmane, additional, Buet, Emeline, additional, Gallouche, Meghann, additional, Larrat, Sylvie, additional, Giner, Céline, additional, Mallaret, Marie Reine, additional, Morand, Patrice, additional, and Landelle, Caroline, additional

Published
2022
Full Text
View/download PDF

18. Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021

Author

Gaymard, Alexandre, Bosetti, Paolo, Feri, Adeline, Destras, Gregory, Enouf, Vincent, Andronico, Alessio, Burrel, Sonia, Behillil, Sylvie, Sauvage, Claire, Bal, Antonin, Morfin, Florence, Van Der Werf, Sylvie, Josset, Laurence, Blanquart, François, Coignard, Bruno, Cauchemez, Simon, Lina, Bruno, Gault, Elyanne, Moreau, Frédérique, Brichler, Ségolène, Delagrèverie, Héloïse, Descamps, Diane, Charpentier, Charlotte, Rozenberg, Flore, L'Honneur, Anne-Sophie, Veyer, David, Bélec, Laurent, Fourati, Slim, Rodriguez, Christophe, Pawlotsky, Jean-Michel, Fourgeaud, Jacques, Abid, Hanène, Roque-Afonso, Anne-Marie, Fenaux, Honorine, Jary, Aude, Marot, Stéphane, Salmona, Maud, Chaix, Marie-Laure, Morand-Joubert, Laurence, Schnuriger, Aurélie, Juillet, Stéphanie Marque, Bargain, Pauline, Poggi, Cécile, Chollet, Lionel, Guillaume, Clémence, Guinard, Jérôme, Vallet, Sophie, Pilorgé, Léa, Schvoerer, Evelyne, Hartard, Cédric, Castelain, Sandrine, François, Catherine, Ducancelle, Alexandra, Lefeuvre, Caroline, Lepiller, Quentin, Marty-Quinternet, Solène, Bellecave, Pantxika, Tumiotto, Camille, Dina, Julia, Le Gouil, Meriadeg, Henquell, Cécile, Mirand, Audrey, Césaire, Raymond, de Rougemont, Alexis, Auvray, Christelle, Larrat, Sylvie, Némoz, Benjamin, Tinez, Claire, Guigon, Aurélie, Hantz, Sébastien, Rogez, Sylvie, Dos Santos, Georges, Perez, Pascale, Jost, Christelle, Montes, Brigitte, Foulongne, Vincent, Imbert, Berthe-Marie, Bressollette, Céline, Giordanengo, Valérie, Gonfrier, Géraldine, Garcia, Magali, Lévêque, Nicolas, Brodard, Véronique, Moret, Hélène, Thibault, Vincent, Maillard, Anne, Jaffar-Bandjee, Marie-Christine, Gueudin, Marie, Plantier, Jean-Christophe, Pozzetto, Bruno, Pillet, Sylvie, Fafi-Kremer, Samira, Solis, Morgane, Izopet, Jacques, Trémeaux, Pauline, Stefic, Karl, Handala, Lynda, Billaud, Geneviève, Frobert, Emilie, Mérens, Audrey, Bigaillon, Christine, Desroches, Marine, Thepenier, Cédric, Janvier, Frédéric, Otto, Marie-Pierre, Roquebert, Bénédicte, Haïm-Boukobza, Stéphanie, Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] (CNR - laboratoire associé), Institut des Agents Infectieux [Lyon] (IAI), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Hospices Civils de Lyon (HCL), Virpath-Grippe, de l'émergence au contrôle -- Virpath-Influenza, from emergence to control (Virpath), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Modélisation mathématique des maladies infectieuses - Mathematical modelling of Infectious Diseases, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Direction des maladies infectieuses - Infectious Diseases Division [Saint-Maurice], Santé publique France - French National Public Health Agency [Saint-Maurice, France], Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre interdisciplinaire de recherche en biologie (CIRB), Labex MemoLife, École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 (AGIR ), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Laboratoire de Virologie [CHU Amiens], CHU Amiens-Picardie, ANRS - Maladies infectieuses émergentes (ANRS - MIE), Institut National de la Santé et de la Recherche Médicale (INSERM), We acknowledge financial support from Santé publique France (the French national public health agency), the French Ministry of health (Grant COVIDseq), the Consortium for the surveillance and research on emerging pathogens via microbial genomics (EMERGEN) coordinated by Santé publique France and ANRS Maladies Infectieuses Emergentes, the Investissement d’Avenir programme, the Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases programme (grant ANR-10-LABX-62-IBEID), the European Union’s Horizon 2020 research and in-novation programme under grants 101003589 (RECOVER). This work has been supported by the laboratories belonging to the ColVHB network*., ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), European Project: 101003589, H2020-SC1-PHE-CORONAVIRUS-2020,RECOVER(2020), Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] (CNR), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR), Institut Pasteur [Paris], Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, Gestionnaire, Hal Sorbonne Université, Integrative Biology of Emerging Infectious Diseases - - IBEID2010 - ANR-10-LABX-0062 - LABX - VALID, Rapid European COVID-19 Emergency Response research - RECOVER - - H2020-SC1-PHE-CORONAVIRUS-20202020-02-14 - 2022-02-13 - 101003589 - VALID, Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris)

Subjects
Author's Correction, Paris, medicine.medical_specialty, 2019-20 coronavirus outbreak, Lineage (genetic), Coronavirus disease 2019 (COVID-19), Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), viral infections, [SDV]Life Sciences [q-bio], Context (language use), Biology, 03 medical and health sciences, 0302 clinical medicine, Virology, medicine, Humans, MESH: COVID-19, MESH: SARS-CoV-2, 030212 general & internal medicine, 030304 developmental biology, COVID, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, 0303 health sciences, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, MESH: Humans, SARS-CoV-2, MESH: Paris, Public Health, Environmental and Occupational Health, COVID-19, [SDV] Life Sciences [q-bio], MESH: France, 20I/501Y.V1, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, surveillance, France, mutation, Rapid Communication, Demography
Abstract

International audience; The emergence of SARS-CoV-2 variant 20I/501Y.V1 (VOC-202012/1 or GR/501Y.V1) is concerning given its increased transmissibility. We reanalysed 11,916 PCR-positive tests (41% of all positive tests) performed on 7-8 January 2021 in France. The prevalence of 20I/501Y.V1 was 3.3% among positive tests nationwide and 6.9% in the Paris region. Analysing the recent rise in the prevalence of 20I/501Y.V1, we estimate that, in the French context, 20I/501Y.V1 is 52-69% more transmissible than the previously circulating lineages, depending on modelling assumptions.

Published
2021

19. Screening of hepatitis E in patients presenting for acute neurological disorders

Author

Belbézier, Aude, Deroux, Alban, Sarrot-Reynauld, Françoise, Colombe, Barbara, Bosseray, Annick, Wintenberger, Claire, Dumanoir, Perrine, Lugosi, Maxime, Boccon-Gibod, Isabelle, Leroy, Vincent, Maignan, Maxime, Collomb-Muret, Roselyne, Viglino, Damien, Vaillant, Mathieu, Minotti, Lorella, Lagrange, Emeline, Epaulard, Olivier, Dumestre-Perard, Chantal, Lhomme, Sébastien, Lupo, Julien, Larrat, Sylvie, Morand, Patrice, Schwebel, Carole, Vilotitch, Antoine, Bosson, Jean-Luc, and Bouillet, Laurence

Published
2020
Full Text
View/download PDF

22. Myasthenia gravis associated with acute hepatitis E infection in immunocompetent woman

Author

Belbezier, Aude, Deroux, Alban, Sarrot-Reynauld, Francoise, Larrat, Sylvie, and Bouillet, Laurence

Subjects
Women -- Health aspects, Hepatitis E -- Health aspects, Myasthenia gravis -- Health aspects, Health
Abstract

To the Editor: Hepatitis E virus (HEV) is a common cause of acute hepatitis in developing countries. The course of acute hepatitis E is usually benign, except in pregnant women [...]

Published
2014

24. Hepatitis e virus infection after platelet transfusion in an immunocompetent trauma patient

Author

Loyrion, Emmanuelle, Trouve-Buisson, Thibaut, Pouzol, Patricia, Larrat, Sylvie, Decaens, Thomas, and Payen, Jean- Francois

Subjects
Platelet transfusion -- Health aspects, Hepatitis E -- Health aspects, Infection -- Health aspects, Food contamination -- Health aspects, Health
Abstract

In developed countries, hepatitis E virus (HEV) infection usually results from consumption of contaminated meat or water and causes acute liver disease. Hepatitis E illness is usually self-limiting, and severe, [...]

Published
2017
Full Text
View/download PDF

25. Diagnostic accuracy of a rapid RT-PCR assay for point-of-care detection of influenza A/B virus at emergency department admission: A prospective evaluation during the 2017/2018 influenza season

Author

Maignan, Maxime, primary, Viglino, Damien, additional, Hablot, Maud, additional, Termoz Masson, Nicolas, additional, Lebeugle, Anne, additional, Collomb Muret, Roselyne, additional, Mabiala Makele, Prudence, additional, Guglielmetti, Valérie, additional, Morand, Patrice, additional, Lupo, Julien, additional, Forget, Virginie, additional, Landelle, Caroline, additional, and Larrat, Sylvie, additional

Published
2019
Full Text
View/download PDF

26. Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy

Author

Virlogeux, Victor, primary, Berthillon, Pascale, additional, Bordes, Isabelle, additional, Larrat, Sylvie, additional, Crouy, Stéphanie, additional, Scholtès, Caroline, additional, Pradat, Pierre, additional, Maynard, Marianne, additional, Zoulim, Fabien, additional, Leroy, Vincent, additional, Chemin, Isabelle, additional, Trépo, Christian, additional, and Petit, Marie-Anne, additional

Published
2018
Full Text
View/download PDF

28. Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world

Author

Halfon, Philippe, primary, Scholtès, Caroline, additional, Izopet, Jacques, additional, Larrat, Sylvie, additional, Trimoulet, Pascale, additional, Zoulim, Fabien, additional, Alric, Laurent, additional, Métivier, Sophie, additional, Leroy, Vincent, additional, Ouzan, Denis, additional, de Lédinghen, Victor, additional, Mohamed, Sofiane, additional, Pénaranda, Guillaume, additional, Khiri, Hacène, additional, Thélu, Marie-Ange, additional, Plauzolles, Anne, additional, Chiche, Laurent, additional, Bourlière, Marc, additional, and Abravanel, Florence, additional

Published
2018
Full Text
View/download PDF

30. Hepatitis E Virus in Acute Non-Traumatic, Non-Vascular Neurological Injury: A French Monocentric Prospective Study

Author

belbézier, aude, primary, Deroux, Alban, additional, Sarrot-Reynauld, Françoise, additional, Colombe, Barbara, additional, Bosseray, Annick, additional, Wintenberger, Claire, additional, Dumanoir, Perrine, additional, Lugosi, Maxime, additional, Boccond-Gibod, Isabelle, additional, Leroy, Vincent, additional, Maignan, Maxime, additional, Collomb-Muret, Roselyne, additional, Viglino, Damien, additional, Vaillant, Mathieu, additional, Lagrange, Emeline, additional, Epaulard, Olivier, additional, Dumestre-Perard, Chantal, additional, Lupo, Julien, additional, Larrat, Sylvie, additional, Morand, Patrice, additional, Schwebel, Carole, additional, Vilotitch, Antoine, additional, Bosson, Jean-Luc, additional, and Bouillet, Laurence, additional

Published
2018
Full Text
View/download PDF

31. Misidentification of a Hepatitis C Virus (HCV) recombinant form leading to treatment failure with new direct acting antivirals

Author

Decroos, Amandine, de Oliveira, Fabienne, Leoz, Marie, Larrat, Sylvie, Riachi, Ghassan, Mourez, Thomas, Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Unit for Virus Host-Cell Interactions [Grenoble] (UVHCI), Centre National de la Recherche Scientifique (CNRS)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Université Joseph Fourier - Grenoble 1 (UJF), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), and Mzembaba, Sandy

Subjects
[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

32. Estimation of genetic diversity in NS3 region of Hepatitis C virus using 454 pyrosequencing

Author

Kulkarni Om, Francois Olivier, Morand Patrice, Michaël G. B. Blum, and Larrat Sylvie

Subjects
Diversity, NS3, viruses, HCV
Abstract

Viruses are highly diverse in their genetic constitution, both within and between infected hosts. They adapt to the host’s environment with a high mutation rate and make identification and consequent treatment very difficult, especially if the treatment targets a particular genetic feature. Hepatitis C Virus (HCV), which causes nearly 200 million chronic infections worldwide, is being studied using various bioinformatics approaches. It is curable with treatments which vary in dosage and duration based on the genotype of the virus. It is hypothesized that direct antiviral therapies which target viral proteins create a selection pressure in the virus. This ultimately leads to the emergence of viral strains in which the gene coding for the target protein is mutated, further complicating treatment. There is a need for highly accurate genotyping capabilities, so variants are correctly identified and appropriate treatment can be administered. We propose a case study in which viral samples from 45 patients with chronic HCV are being sequenced using a Roche GS Junior at different stages of treatment. Using variant callers like GS Amplicon Variant Analyzer and other tools the variants in the viral population over the course of treatment are observed. It is of interest to know if the increase in viral diversity is linked with onset of the treatment, and the difference in viral population for each outcome of the treatment (responders vs non-responders). This would ultimately help in understanding the evolution of the virus and further insights into drug designing and personalized treatment.

Published
2016
Full Text
View/download PDF

33. Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity

Author

Ducancelle, Alexandra, Pivert, Adeline, Bertrais, Sandrine, Boursier, Jérôme, Balan, Viorica, Veillon, Pascal, Le Guillou-Guillemette, Hélène, Thibault, Vincent, Castelain, Sandrine, Roquebert, Bénédicte, Coste-Burel, Marianne, Mackiewicz, Vincent, Schvoerer, Evelyne, Larrat, Sylvie, Maylin, Sarah, Alain, Sophie, Loustaud-Ratti, Véronique, Gordien, Emmanuel, Gozlan, Joël, Brodard, Véronique, Chevaliez, Stéphane, Calès, Paul, Lunel-Fabiani, Françoise, Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Laboratoire de virologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Pontchaillou [Rennes], Unité de Virologie clinique et fondamentale (UVCF), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Stress, Immunité, Pathogènes (SIMPA), Université de Lorraine (UL), Service de Virologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Institut de biologie structurale (IBS - UMR 5075 ), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)

Subjects
PC mutation, Adult, Liver Cirrhosis, Male, Hepatitis B virus, HBV genotype, Severity of Illness Index, BCP mutation, Hepatitis B, Chronic, Sex Factors, G1896A, Risk Factors, A1762T/G1764A, Humans, Promoter Regions, Genetic, ComputingMilieux_MISCELLANEOUS, Aged, Hepatitis B Surface Antigens, Virulence, fibrosis, Age Factors, Middle Aged, Hepatitis B, G1899A, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, DNA, Viral, Mutation, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female
Abstract

The impact of basal core promoter (BCP) and precore (PC) mutants of the hepatitis B virus (HBV) on liver disease severity remains controversial. The aim of the present study was to screen BCP and PC mutations in 252 HBV surface antigen (HBsAg) positive carriers in France and to assess relationships between these mutations and severe fibrosis.Direct sequencing of the precore/core gene was used to detect A1762T/G1764A and G1757A mutations in the BCP and G1896A and G1899A mutations in the PC region.The prevalences of A1762T/G1764A, G1757A, G1896A, and G1899A mutations were 34.1%, 38.7%, 54.9%, and 29.3% (P 0.001), respectively. The independent predictors of severe fibrosis (≥F3 Metavir) were older age (P 0.001), male gender (P = 0.012), elevated alanine aminotransferase (P 0.001), and the double A1762T/G1764A mutant with no other mutations (P = 0.011). Interestingly, the association of the G1899A mutation with the double A1762T/G1764A mutant significantly counteracted the deleterious effect of the sole double A1762T/G1764A mutant (odds ratio [OR] = 0.28 vs. OR = 3.55, respectively, P = 0.028).Patients with the A1762T/G1764A mutation have a higher risk of severe fibrosis. The G1899A mutation is a protective factor against severe fibrosis that counteracted the deleterious effect of the A1762T/G1764A mutation. Finally, host phenotypic and HBV genotypic markers independently predict fibrosis severity.

Published
2015

34. Apport du séquençage nouvelle génération au typage MLST de Pneumocysits jirovecii , dans le cadre d’une épidémie chez des patients transplantés d’organe solide

Author

Charpentier, Eléna, primary, Garnaud, Cécile, additional, Wintenberger, Claire, additional, Bailly, Sébastien, additional, Murat, Jean-Benjamin, additional, Rendu, John, additional, Pavese, Patricia, additional, Drouet, Thibault, additional, Augier, Caroline, additional, Malvezzi, Paolo, additional, Thiébaut-Bertrand, Anne, additional, Mallaret, Marie-Reine, additional, Epaulard, Olivier, additional, Cornet, Muriel, additional, Larrat, Sylvie, additional, and Maubon, Danièle, additional

Published
2017
Full Text
View/download PDF

35. New insights into HCV replication in original cells from Aedes mosquitoes

Author

Fallecker, Catherine, primary, Caporossi, Alban, additional, Rechoum, Yassine, additional, Garzoni, Frederic, additional, Larrat, Sylvie, additional, François, Olivier, additional, Fender, Pascal, additional, Morand, Patrice, additional, Berger, Imre, additional, Petit, Marie-Anne, additional, and Drouet, Emmanuel, additional

Published
2017
Full Text
View/download PDF

36. Added Value of Next-Generation Sequencing for Multilocus Sequence Typing Analysis of aPneumocystis jiroveciiPneumonia Outbreak1

Author

Charpentier, Elena, primary, Garnaud, Cécile, additional, Wintenberger, Claire, additional, Bailly, Sébastien, additional, Murat, Jean-Benjamin, additional, Rendu, John, additional, Pavese, Patricia, additional, Drouet, Thibault, additional, Augier, Caroline, additional, Malvezzi, Paolo, additional, Thiébaut-Bertrand, Anne, additional, Mallaret, Marie-Reine, additional, Epaulard, Olivier, additional, Cornet, Muriel, additional, Larrat, Sylvie, additional, and Maubon, Danièle, additional

Published
2017
Full Text
View/download PDF

37. Baseline and Post-Treatment Hepatitis C NS5A Resistance in Relapsed Patients from a Multicentric Real-Life Cohort

Author

Halfon, Philippe, primary, Scholtès, Caroline, additional, Izopet, Jacques, additional, Larrat, Sylvie, additional, Trimoulet, Pascale, additional, Zoulim, Fabien, additional, Alric, Laurent, additional, Métivier, Sophie, additional, Leroy, Vincent, additional, Ouzan, Denis, additional, De Lédinghen, Victor, additional, Mohamed, Sofane, additional, Pénaranda, Guillaume, additional, Khiri, Hacène, additional, Thélu, Marie-Ange, additional, Plauzolles, Anne, additional, Chiche, Laurent, additional, Bourlière, Marc, additional, and Abravanel, Florence, additional

Published
2017
Full Text
View/download PDF

38. Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma

Author

Le Guillou-Guillemette, Hélène, primary, Pivert, Adeline, additional, Bouthry, Elise, additional, Henquell, Cécile, additional, Petsaris, Odile, additional, Ducancelle, Alexandra, additional, Veillon, Pascal, additional, Vallet, Sophie, additional, Alain, Sophie, additional, Thibault, Vincent, additional, Abravanel, Florence, additional, Rosenberg, Arielle A., additional, André-Garnier, Elisabeth, additional, Bour, Jean-Baptiste, additional, Baazia, Yazid, additional, Trimoulet, Pascale, additional, André, Patrice, additional, Gaudy-Graffin, Catherine, additional, Bettinger, Dominique, additional, Larrat, Sylvie, additional, Signori-Schmuck, Anne, additional, Saoudin, Hénia, additional, Pozzetto, Bruno, additional, Lagathu, Gisèle, additional, Minjolle-Cha, Sophie, additional, Stoll-Keller, Françoise, additional, Pawlotsky, Jean-Michel, additional, Izopet, Jacques, additional, Payan, Christopher, additional, Lunel-Fabiani, Françoise, additional, and Lemaire, Christophe, additional

Published
2017
Full Text
View/download PDF

39. Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity

Author

Ducancelle, Alexandra, primary, Pivert, Adeline, additional, Bertrais, Sandrine, additional, Boursier, Jérôme, additional, Balan, Viorica, additional, Veillon, Pascal, additional, le Guillou‐Guillemette, Hélène, additional, Thibault, Vincent, additional, Castelain, Sandrine, additional, Roquebert, Bénédicte, additional, Coste‐Burel, Marianne, additional, Mackiewicz, Vincent, additional, Schvoerer, Evelyne, additional, Larrat, Sylvie, additional, Maylin, Sarah, additional, Alain, Sophie, additional, Loustaud‐Ratti, Véronique, additional, Gordien, Emmanuel, additional, Gozlan, Joël, additional, Brodard, Véronique, additional, Chevaliez, Stéphane, additional, Calès, Paul, additional, and Lunel‐Fabiani, Françoise, additional

Published
2016
Full Text
View/download PDF

40. Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin

Author

Larrat, Sylvie, Vallet, Sophie, David-Tchouda, Sandra, Caporossi, Alban, Margier, Jennifer, Ramière, Christophe, Scholtès, Caroline, Haïm-Boukobza, Stéphanie, Roque-Afonso, Anne-Marie, Besse, Bernard, André-Garnier, Elisabeth, Mohamed, Sofiane, Halfon, Philippe, Pivert, Adeline, Leguillou-Guillemette, Hélène, Abravanel, Florence, Guivarch, Matthieu, Mackiewicz, Vincent, Lada, Olivier, Mourez, Thomas, Plantier, Jean-Christophe, Baazia, Yazid, Alain, Sophie, Hantz, Sébastien, Thibault, Vincent, Gaudy-Graffin, Catherine, Bouvet, Dorine, Mirand, Audrey, Henquell, Cécile, Gozlan, Joël, Lagathu, Gisèle, Pronier, Charlotte, Velay, Aurélie, SCHVOERER, Evelyne, Trimoulet, Pascale, Fleury, Hervé, Bouvier-Alias, Magali, BROCHOT, Etienne, Duverlie, Gilles, Maylin, Sarah, Gouriou, Stéphanie, Pawlotsky, Jean-Michel, Morand, Patrice, Plantier, Christophe, Tang, Y.-W., Unit for Virus Host-Cell Interactions [Grenoble] (UVHCI), Université Joseph Fourier - Grenoble 1 (UJF)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Universitaire de Biodiversité et Ecologie Microbienne (LUBEM), Université de Brest (UBO), Centre d'Investigation Clinique - Innovation Technologique - INSERM - CHU de Grenoble (CIC-IT Grenoble (CIT803)), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes (UGA), Centre Hospitalier Universitaire [Grenoble] (CHU), Biologie cellulaire des infections virales – Cell biology of viral infection, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Laboratoire de virologie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse, Hôtel-Dieu de Nantes, Alphabio Laboratory, Hôpital Européen [Fondation Ambroise Paré - Marseille], Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre de Physiopathologie Toulouse Purpan (ex IFR 30 et IFR 150) (CPTP), Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UPS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Beaujon, Centre de recherche sur l'Inflammation (CRI), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Rouen, Normandie Université (NU), Service de bactériologie-Virologie-Hygiène [Avicenne], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Avicenne, Université de Limoges (UNILIM), Service de Bactériologie, Virologie, Hygiène [CHU Limoges], CHU Limoges, CHU Pontchaillou [Rennes], Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidémiologie et pathogénie des infections à entérovirus (EPIE), Université d'Auvergne - Clermont-Ferrand I (UdA), Laboratoire Microorganismes : Génome et Environnement - Clermont Auvergne (LMGE), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Antoine [APHP], Virology Laboratory, General Hospital Papageorgiou, Service de Virologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Stress, Immunité, Pathogènes (SIMPA), Université de Lorraine (UL), Service de virologie et d'immunologie biologique, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence Virus des hépatites B, C et Delta, Institut National de la Transfusion Sanguine [Paris] (INTS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Unité de Virologie clinique et fondamentale EA 4294, CHU Amiens-Picardie, Institut de biologie de Lille - IBL (IBLI), Université de Lille, Sciences et Technologies-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Centre National de la Recherche Scientifique (CNRS)-Université de Lille, Droit et Santé, Laboratoire de Virologie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Laboratoire de virologie moléculaire et structurale, CHU Grenoble, Centre National de la Recherche Scientifique (CNRS)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Université Joseph Fourier - Grenoble 1 (UJF), Laboratoire de Parasitologie et Mycologiede [CHRU Brest], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Unité d'évaluation clinique et médico-économique [CHU Grenoble] (Département de la recherche clinique et de l'innovation), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Virologie [HCL-Hôpital de la Croix Rousse], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de Virologie [Villejuif], Hôpital Paul Brousse, Université Paris-Sud - Paris 11 - Faculté de médecine (UP11 UFR Médecine), Université Paris-Sud - Paris 11 (UP11), Laboratoire de Virologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), ALPHABIO - Laboratoire de biologie médicale, Laboratoire de virologie [CHU Angers], PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Laboratoire de Virologie [CHU Purpan, Toulouse], Institut Fédératif de Biologie (IFB) - Hôpital Purpan, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de virologie [Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Département de microbiologie : Bactério, Virologie, Parasito, Hygiène, Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de bactériologie-virologie [Tours], Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre national de référence du VIH INSERM U966, Université de Tours (UT), CHU Clermont-Ferrand, Laboratoire de Virologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Laboratoire de Virologie [Rennes] = Virology [Rennes], Institut National de la Transfusion Sanguine [Paris] (INTS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de bactériologie - hygiène [CHU Amiens], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis [AP-HP] (AP-HP), Unit for Virus Host-Cell Interactions [Grenoble] ( UVHCI ), Université Joseph Fourier - Grenoble 1 ( UJF ) -European Molecular Biology Laboratory [Grenoble] ( EMBL ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire Universitaire de Biodiversité et Ecologie Microbienne ( LUBEM ), Université de Brest ( UBO ), ThEMAS, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble ( TIMC-IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Institut d'Enseignement Supérieur et de Recherche en Alimentation, Santé Animale, Sciences Agronomiques et de l'Environnement ( VetAgro Sup ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Institut d'Enseignement Supérieur et de Recherche en Alimentation, Santé Animale, Sciences Agronomiques et de l'Environnement ( VetAgro Sup ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -CHU Grenoble, Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-CHU Grenoble, Pathogénèse et traitement de l'hépatite fulminante et du cancer du foie, Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Grenoble Alpes - UFR Médecine ( UGA UFRM ), Université Grenoble Alpes ( UGA ), Internal Medicine and Infectious Diseases Department, European Hospital and Alphabio Laboratory, Centre Hospitalier Universitaire d'Angers ( CHU Angers ), PRES Université Nantes Angers Le Mans ( UNAM ), Laboratoire de Virologie [Toulouse], CHU Toulouse [Toulouse], Service d'hépatologie, Assistance publique - Hôpitaux de Paris (AP-HP) ( APHP ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Hôpital Beaujon, Hôpital Bichat - Claude Bernard, Centre de recherche sur l'Inflammation ( CRI ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de Recherche Biomédicale des Armées ( IRBA ), CHU Avicenne, Service de virologie, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP) ( APHP ) -CHU Pitié-Salpêtrière [APHP], Morphogénèse et antigénicité du VIH et du virus des Hépatites ( MAVIVH ), Université de Tours-Centre Hospitalier Régional Universitaire de Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de Calcul de l'IN2P3 ( CC-IN2P3 ), Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), CHU Strasbourg, Virology Laboratory, Bordeaux University Hospital, Bordeaux, France, Microbiologie cellulaire et moléculaire et pathogénicité ( MCMP ), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique ( CNRS ), Faculté de Médecine, CHU Henri Mondor, Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, SCHVOERER, Evelyne, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Antoine [AP-HP], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Département de microbiologie : Bactério, Virologie, Parasito, Hygiène-Hôpital Charles Nicolle [Rouen]-CHU Rouen, and Université de Tours

Subjects
Male, Hepacivirus, Viral Nonstructural Proteins, medicine.disease_cause, Gastroenterology, Telaprevir, chemistry.chemical_compound, Pegylated interferon, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Hepacivirus, MESH: Treatment Outcome, MESH: Inhibitory Concentration 50, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, MESH: Aged, education.field_of_study, MESH: Drug Resistance, Viral, MESH: Middle Aged, MESH: Protease Inhibitors, Hepatitis C, Middle Aged, 3. Good health, MESH: Hepatitis C, Chronic, Treatment Outcome, MESH: Oligopeptides, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, MESH: Interferon-alpha, Viral load, Oligopeptides, medicine.drug, Microbiology (medical), MESH: Antiviral Agents, Adult, medicine.medical_specialty, Proline, Hepatitis C virus, Population, Mutation, Missense, Antiviral Agents, Inhibitory Concentration 50, MESH: Ribavirin, Internal medicine, Boceprevir, Virology, Drug Resistance, Viral, Ribavirin, medicine, Humans, Protease Inhibitors, education, Aged, Retrospective Studies, MESH: Mutation, Missense, MESH: Humans, MESH: Proline, business.industry, Interferon-alpha, MESH: Adult, MESH: Retrospective Studies, Hepatitis C, Chronic, medicine.disease, MESH: Male, chemistry, Immunology, MESH: Viral Nonstructural Proteins, business, MESH: Female, [ SDV.BBM.BS ] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM]
Abstract

The pretherapeutic presence of protease inhibitor (PI) resistance-associated variants (RAVs) has not been shown to be predictive of triple-therapy outcomes in treatment-naive patients. However, they may influence the outcome in patients with less effective pegylated interferon (pegIFN)-ribavirin (RBV) backbones. Using hepatitis C virus (HCV) population sequence analysis, we retrospectively investigated the prevalence of baseline nonstructural 3 (NS3) RAVs in a multicenter cohort of poor IFN-RBV responders (i.e., prior null responders or patients with a viral load decrease of 3-fold shift in 50% inhibitory concentration (IC 50 ) for telaprevir or boceprevir, T54S was the most frequently detected mutation (3.9%), followed by A156T, R155K (0.7%), V36M, and V55A (0.35%). Mutations were more frequently found in patients infected with genotype 1a (7.5 to 23.6%) than 1b (3.3 to 19.8%) ( P = 0.03). No other sociodemographic or viroclinical characteristic was significantly associated with a higher prevalence of RAVs. No obvious effect of baseline RAVs on viral load was observed. In this cohort of poor responders to IFN-RBV, no link was found with a sustained virological response to triple therapy, regardless of the algorithm used for the detection of mutations. Based on a cross-study comparison, baseline RAVs are not more frequent in poor IFN-RBV responders than in treatment-naive patients and, even in these difficult-to-treat patients, this study demonstrates no impact on treatment outcome, arguing against resistance analysis prior to treatment.

Published
2015

41. Inhibition du cycle lytique du Virus Epstein-Barr par ARN interférence

Author

Larrat, Sylvie, Laboratoire de virologie moléculaire et structurale (LVMS), Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Université Joseph-Fourier - Grenoble I, Patrice Morand(PMorand@chu-grenoble.fr), and Larrat, Sylvie

Subjects
[SDV] Life Sciences [q-bio], Virus Epstein-Barr, RNA interference, viruses, [SDV]Life Sciences [q-bio], protease, lytic cycle, Epstein-Barr Virus, cycle lytique, ARN interférence
Abstract

The lytic cycle of EBV plays an important role in pathologies associated with this virus. Involved in manufacturing of the viral capsid, protease (PR) is essential for infectious virions production. It represents thereby a prime target for a therapeutic strategy to inhibit viral replication. In this work, the therapeutic efficiency of siRNA targeting EBV-PR was tested on 293 epithelial cells transfected with EBV B95-8 genome. The decrease of PR mRNA was measured by quantitative RT-PCR, the amount of expressed protein by Western blot, and the number of produced infectious viral particles by super-infection of Raji cells. The efficiency of the best siRNA anti-PR was compared to that of anti-DNA polymerase anti-CMV drug and then assessed in combination with siRNA targeting other lytic cycle proteins of EBV. The anti-PR siRNA tested here allow getting a 70% decrease of PR mRNA, 35% of protein and 95% of infectious viral particles number. Compared to anti-DNA polymerase, only the siRNA anti-PR enables a significant reduction of infectious viral particles number and its association with ganciclovir increases even more its effectiveness (p, Le cycle lytique de l'EBV joue un rôle important dans les pathologies associées à ce virus. Participant à la fabrication de la capside virale, la protéase (PR) est essentielle à la production de virions infectieux. Elle représente ainsi une cible de choix pour une stratégie thérapeutique visant à inhiber la réplication virale. Dans ce travail, l'efficacité thérapeutique de siRNA ciblant EBV-PR a été évaluée sur des cellules épithéliales 293 transfectées avec le génome d'EBV B95-8. La diminution de l'ARNm PR a été mesurée par RT-PCR quantitative, la quantité de protéine exprimée, par Western blot, et le nombre de particules virales infectieuses produites, par sur-infection de cellules Raji. L'efficacité du meilleur siRNA anti-PR a été comparée à celle de drogues anti-ADN polymérase anti-CMV puis évaluée en combinaison avec des siRNA ciblant d'autres protéines du cycle lytique d'EBV. Les siRNA anti-PR testés ici permettent d'obtenir une diminution de 70% de l'ARNm PR, de 35% de la protéine et de 95% du nombre de particules virales infectieuses. Comparés aux anti-ADN polymérase, seul le siRNA anti-PR permet d'obtenir une diminution significative de nombre de particules virales infectieuses et son association au ganciclovir permet encore d'augmenter cette efficacité (p

Published
2010

42. Prevalence and characterization of NS5A resistance associated variants (RAVs) in patients who relapsed following exposure to NS5A inhibitors

Author

Penaranda, Guillaume, primary, Halfon, Philippe, additional, Scholtès, Caroline, additional, Mohamed, Sofiane, additional, Leroy, Vincent, additional, Bourlière, Marc, additional, Ouzan, Denis, additional, Pénaranda, Guillaume, additional, Khiri, Hacène, additional, Polverel, Laura, additional, Zoulim, Fabien, additional, Thélu, Marie-Ange, additional, and Larrat, Sylvie, additional

Published
2016
Full Text
View/download PDF

44. Hepatitis E virus infection in sheltered homeless persons, France

Author

Larrat, Sylvie, Gaillard, Stephanie, Baccard, Monique, Piroth, Lionel, Cacoub, Patrice, Pol, Stanislas, Perronne, Christian, Carrat, Fabrice, and Morand, Patrice

Subjects
Hepatitis E -- Health aspects, Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Homeless persons -- Health aspects, Health
Abstract

To the Editor: Kaba et al. (1) reported a seroprevalence of 11.6% for hepatitis E virus (HEV) among homeless persons in the city of Marseille, located in southern France, and [...]

Published
2012
Full Text
View/download PDF

45. Evaluation of the cobas® GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures.

Author

Némoz, Benjamin, Roger, Léa, Leroy, Vincent, Poveda, Jean-Dominique, Morand, Patrice, and Larrat, Sylvie

Subjects
HEPATITIS C virus, HEPATITIS C treatment, VIRAL load, VIRAL genomes, TREATMENT effectiveness, GENETICS
Abstract

Direct-acting antiviral (DAA) drug performances depend on the viral genotype. So international recommendations give typing of the virus a prerequisite for treatment choice and patient management. Commercially available HCV genotyping kits are scarce and this analysis is often in-house using tedious PCRs and Sanger sequencing, leading to a lack of standardization. A newly commercialized HCV genotyping assay based on real-time PCR has been developed by Roche Diagnostics (Mannheim, Germany). We compared this new assay with our in-house PCRs -sequencing technique on 101 regular samples and 81 LiPA failures or low viral load samples. No genotype or 1a/1b subtype mismatch was observed. Two samples were misidentified at the subtype level without clinical impact. Three genotype 1b and two genotype 1a samples with low viral load could not be subtyped. Nevertheless, 13 (13%) samples from the regular panel and 35 (43%) from the more difficult-to-type panels failed to give results on first pass with the Roche kit. Failures were mostly associated with genotype 3 subtype a, with genotype 4 subtype non-a, or with viral loads <200 IU/mL (p = 0.0061). The workflow allowed a non-specialized technician to obtain results in less than 4 hours whereas 2 to 3 days and experienced staff were required with the in-house assay. In conclusion, the Roche cobas® HCV GT kit is easy and rapid to use and provides reliable results. The high rate of uninterpretable results particularly for low viral load samples and less frequent genotypes, and the absence of subtyping for non-genotype 1 could require sending complex samples to a specialized laboratory. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

49. Ultradeep Pyrosequencing of NS3 To Predict Response to Triple Therapy with Protease Inhibitors in Previously Treated Chronic Hepatitis C Patients

Author

Larrat, Sylvie, primary, Kulkarni, Om, additional, Claude, Jean-Baptiste, additional, Beugnot, Réjane, additional, Blum, Michaël G. B., additional, Fusillier, Katia, additional, Lupo, Julien, additional, Tremeaux, Pauline, additional, Plages, Agnès, additional, Marlu, Alice, additional, Duborjal, Hervé, additional, Signori-Schmuck, Anne, additional, Francois, Olivier, additional, Zarski, Jean-Pierre, additional, Morand, Patrice, additional, and Leroy, Vincent, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results